RAPP
Rapport Therapeutics, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$45.77
−3.95%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 20.0M | — | — | — | — |
| Cost of Revenue | — | — | — | — | 15.0K |
| Gross Profit | 20.0M | — | — | — | (15.0K) |
| Operating Expenses | |||||
| R&D Expense | 136.7M | 94.8M | 60.9M | 28.0M | 9.1M |
| SG&A Expense | 36.8M | 30.3M | 22.1M | 8.2M | 1.4M |
| General & Admin Expense | 36.8M | 30.3M | 22.1M | 8.2M | 1.4M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | (128.8K) |
| Total Operating Expenses | 173.5M | 125.1M | 83.1M | 36.2M | 10.4M |
| Cost and Expenses | 173.5M | 125.1M | 83.1M | 36.2M | 10.4M |
| Operating Income (EBIT) | (153.5M) | (125.1M) | (83.1M) | (36.2M) | (10.4M) |
| Non-Operating | |||||
| Interest Income | 16.4M | 13.6M | 12.1M | 2.5M | — |
| Interest Expense | — | — | — | — | 285.0K |
| Net Interest Income | 16.4M | 13.6M | 12.1M | 2.5M | (285.0K) |
| Other Non-Op Income/Expense | 16.4M | 13.6M | 4.7M | 1.4M | (285.0K) |
| Non-Operating Income (excl Interest) | (4.2M) | — | — | — | — |
| EBT (Pre-Tax Income) | (137.2M) | (111.5M) | (78.3M) | (34.8M) | (10.7M) |
| Income Tax Expense | — | — | — | 10.0K | — |
| Bottom Line | |||||
| Net Income | (137.2M) | (111.5M) | (78.3M) | (34.8M) | (10.7M) |
| Earnings from Cont. Ops | (137.2M) | (111.5M) | (78.3M) | (34.8M) | (10.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (137.2M) | (111.5M) | (78.3M) | (34.8M) | (10.7M) |
| Per Share | |||||
| Basic EPS | ($3.04) | ($2.86) | ($3.78) | ($0.95) | ($0.29) |
| Diluted EPS | ($3.04) | ($2.86) | ($3.78) | ($0.95) | ($0.29) |
| Revenue Per Share | $0.42 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 47.5M | 47.0M | 20.7M | 18.1M | 20.1M |
| Diluted Shares Outstanding | 47.5M | 47.0M | 20.7M | 18.1M | 20.1M |
| Profitability Metrics | |||||
| EBITDA | (148.1M) | (124.1M) | (82.2M) | (36.1M) | (10.4M) |
| D&A | 1.2M | 1.0M | 839.0K | 112.0K | 15.0K |
| EBIT | (149.3M) | (125.1M) | (83.1M) | (36.2M) | (10.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026